Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Stroke. 2008 Jul 31;39(10):2830–2836. doi: 10.1161/STROKEAHA.108.515684

Figure 3.

Figure 3

Photomicrographs show PAR-1 (A and B) and platelet (C and D) immunoreactive vessels in the ischemic boundary of the cortex (area 2 of Figure 1A) from representative rats treated with rtPA alone (A and C) or S-0139 in combination with rtPA (B and D). E and F, Quantitative data of PAR-1 and thrombocyte immunoreactive vessels (n=6 per group), respectively. Please see methods for details of quantification of PAR-1 and thrombocyte immunoreactive vessels. Bar=25 µm (A to D). Monotherapy of rtPA was administered 4 hours after stroke, whereas combination therapy of S-0139 and rtPA was given 2 and 4 hours after stroke, respectively.